Fei Hua, PhD LinkedIn

Vice President of Modeling and Simulation Services

Modeling & Simulation

Dr. Fei Hua is a trained biologist and systems modeler with 11 years of drug discovery and development experience, working in a variety of disease areas with both large and small molecules. She previously worked at Pfizer Inc. in non-clinical groups to build systems biology models to help target differentiation, lead selection and biomarker identification. She then moved to the clinical group as a clinical pharmacology lead, where in addition to the traditional roles as clinical pharmacologist, she establish the first example of applying QSP models to address clinical development questions for the group. Over the years, Fei developed skills to integrate all the available information and build fit-for-purpose models to address questions and drive business decisions in a timely manner.

Fei obtained her Bachelor of Science from Tsinghua University, Beijing, China in the Department of Biological Sciences and her Ph.D. from the Department of Physiology at Cornell University, where she started working on mathematical models for cardiac arrhythmia. During her postdoctoral training at the Department of Biomedical Engineering at MIT, she worked on systems models of apoptosis pathways. During her training, Fei has always worked in the lab in parallel with model building to generate data that feeds into the model.

Fei Hua, PhD

I love using modeling as an approach to integrate all the information to better inform drug R&D decisions.

Key Research

  • Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions
  • A next generation mathematical model for the in vitro to clinical translation of T-cell engagers
  • Quantitative systems pharmacology modeling provides insight into inter-mouse variability of Anti-CTLA4 response
  • Early Feasibility Assessment: A Method for Accurately Predicting Biotherapeutic Dosing to Inform Early Drug Discovery Decisions
  • Quantitative systems pharmacology model for Alzheimer’s disease to predict the effect of aducanumab on brain amyloid
All publications

Interested in speaking with an expert?

We'll put you in touch with the right person on our team. 

Schedule Consultation